(Sharecast News) - Convatec reiterated its full-year guidance on Tuesday after delivering first-half results in line with expectations, with the medical products group forecasting stronger revenue and margins in the second half.
The FTSE 100 company narrowed its forecast for 2026 organic revenue growth, excluding InnovaMatrix, to between 5.5% and 6.5%,...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE